J01DI02 - Ceftaroline Fosamil |
Not porphyrinogenic |
NP |
Side effects
Common adverse reactions of ceftaroline that can be confused with an acute porphyric attack are diarrhoea, nausea, vomiting and abdominal pains. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Ceftaroline is not a substrate, inhibitor or inducer of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Cephalosporin antibiotic
Therapeutic characteristics
Ceftaroline is indicated for the treatment of complicated skin and soft tissue infections (cSSTI) and community acquired pneumonia (CAP). It is administered by intravenous infusion. Terminal elimination half-life is 2.5 hours.
Metabolism and pharmakokinetics
Ceftaroline fosamil is a prodrug that is converted into the active drug ceftaroline in plasma by phosphatase enzymes (SPC). It is mainly excreted renally (88 %).
Ceftaroline is not metabolized by CYP450 enzymes and is not suspected to be an inhibitor or inducer of CYP450 enzymes (Laudano 2011, SPC). No drug-drug interactions with ceftaroline as a perpetrator have been reported in the literature (Lexi-Interact).
References
- Scientific articles
- Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8. PMID 21482565. #3177
- Government bodies
- #1302
- Drug interaction databases
- Lexi-Interact in UpToDate. Ceftaroline fosamil: Drug interaction program. #3178
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Zinforo). #3179
Similar drugs
© NAPOS 2024